ADRX

12.9198.76%
YH

Ying Huang

Independent Director

Dr. Ying Huang, Ph.D., is Chief Executive Officer (CEO) of K2 Therapeutics. Dr. Huang serves as an Independent Director of ADARx Pharmaceuticals, Inc. from July 2026. Dr. Huang serves as Independent Director of TCGX Acquisition Corp. from August 4, 2026. Dr. Huang serves as a director of Quanta Therapeutics, Inc. and Third Arc Bio, Inc. Previously, he served as Chief Executive Officer of Legend Biotech Corporation since November 06, 2020 until July 24, 2026 and served as its Director since December 2021 until July 24, 2026. Since joining Legend Biotech in July 2019, Dr. Huang played a central role during the company's crossover round financing and IPO, which was among the largest biotech IPOs of 2020. In addition to his responsibility for Legend Biotech's financial function, he is a core member of the Legend team that manages the company's collaborative efforts. Dr. Huang had been Chief Financial Officer of Legend Biotech Corporation since July 2019 until May 09, 2022 and was its Interim Chief Executive Officer since September 21, 2020 until November 06, 2020. Dr. Huang serves as the Chief Executive Officer and Chief Financial Officer at Genscript Biotech Corporation. Prior to Legend, Dr. Huang spent more than a decade as a biotechnology analyst, as Managing Director and Head of Biotech Equity Research at BofA Securities, Inc. from August 2014 to July 2019, where he led a team of analysts covering more than 30 biotechnology companies including Amgen, Gilead, Celgene, Biogen and others that encompass a wide range of therapeutic areas. Dr. Huang has been a biotechnology analyst since 2007 and previously worked at Wachovia and Credit Suisse. He was a Research Analyst at Barclays PLC, Research Division until May 2014 and served as a Senior Analyst and Director at the firm. He served as a Senior Equity Analyst at Gleacher & Company, Inc., Research Division since August 2010 and also its Vice President. Prior to that, he was a Vice President and Research Analyst at Crédit Suisse AG, Research Division covering small-cap and mid-cap biotech stocks. Dr. Huang was an Associate Analyst at Wells Fargo Securities, LLC, Research Division and began his Wall Street career at the firm, as a member of the biotechnology research team in 2007. He ranked Best Up-and-Comer in biotechnology in the Institutional Investor All-America Research Poll in 2011 and 2012. Prior to his Wall Street career, Dr. Huang was a Principal Scientist at Schering-Plough (now Merck & Co.) in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. Dr. Huang has co-authored multiple peer-reviewed journal articles and ten United States patents. Dr. Huang received his M.A., M.Phil. and Ph.D. in Chemistry from Columbia University and also studied at Columbia Business School and in the Special Class for the Gifted Young at the University of Science and Technology of China.

Positions